Overview of Intergrip

Property	Description
Active ingredient	Paracetamol, Chlorphenamine, Caffeine
Form	Oral Tablet
Pharmacological class	Combination Analgesic and H1-Antihistamine
General Purpose	Broad symptomatic relief for minor systemic discomfort
Origin	Synthetic

What Type of Medicine is Intergrip?

Intergrip is defined as a fixed-dose combination (FDC) preparation, a medicine containing two or more active ingredients in a single unit, such as an oral tablet. Pharmacologically, it is classified as a combination analgesic and H1-antihistamine. This FDC represents an established formulation strategy clinically recognized for its synergistic effect in managing multiple symptoms concurrently. The three active components are synthetically derived, and the medicine is typically administered via the oral route. This structural design distinguishes the product from single-component analgesics, positioning it for use in scenarios where both pain/fever and associated general discomfort are present.

Composition and General Purpose

The composition of Intergrip utilizes the active ingredients: Paracetamol (Acetaminophen), Chlorphenamine maleate, and Caffeine. Paracetamol delivers the analgesic and antipyretic actions. Chlorphenamine, an H1-antihistamine, helps to modulate specific bodily responses, which is a key compositional distinction not found in plain analgesic tablets. The inclusion of Caffeine provides a mild Central Nervous System (CNS) stimulant action. The overall general purpose of this combination preparation is to deliver broad, symptomatic relief by leveraging these three complementary mechanisms to improve the patient's general comfort and state of well-being.

Regulatory References

Pharmacology of Caffeine (NIH/NCBI)

What side effects are possible with Intergrip?

Possible side effects and safety information

The officially documented safety profile for this combination preparation (Paracetamol, Chlorphenamine, Caffeine) is based on adverse reactions and safety characteristics defined in government-approved regulatory labeling, such as the Summary of Product Characteristics (SmPC) and FDA DailyMed documents.

Adverse reactions are classified by frequency and System-Organ Class (SOC) as observed during clinical use. The most frequently documented effects often reflect the properties of the antihistamine component, Chlorphenamine.

Adverse Reaction Classification

Classification	Examples of Officially Documented Effects
Very Common	Sedation, Somnolence (Drowsiness)
Common	Headache, Dizziness, Nausea, Vomiting, Dry mouth
Rare/Very Rare	Serious Skin Reactions (e.g., Stevens-Johnson Syndrome), Blood Dyscrasias (e.g., Agranulocytosis)

Side effects have been officially reported across multiple SOC categories, including Nervous System Disorders, Gastrointestinal Disorders, Psychiatric Disorders, and Cardiac Disorders (e.g., palpitations, tachycardia).

Serious Safety Considerations

Regulatory labeling highlights the critical risk of Severe Hepatotoxicity (liver damage) associated with the Paracetamol component. Exceeding the maximum recommended dose is explicitly linked to this risk, which can lead to acute hepatic failure. Furthermore, rare but serious systemic risks include Severe Allergic Reactions and Serious Skin Reactions.

Population and Exposure Safety Notes

The regulatory safety profile includes specific statements regarding certain patient groups. Individuals with severe hepatic impairment are typically contraindicated due to the Paracetamol component. Older adults and children may be more susceptible to anticholinergic effects, which can sometimes manifest as paradoxical excitation or confusion. Regarding exposure, regulatory documents note that regular, prolonged daily use of Paracetamol may officially affect certain existing treatments, and symptoms of severe Paracetamol overdose may have a delayed onset.

Overdose and Emergency Response

Overdose and when to seek help

The information in this section is based strictly on the official content and instructions provided by governmental regulatory authorities (e.g., FDA, EMA, national health agencies) regarding overdose of this combination medicine.

Officially Documented Overdose Manifestations

Symptoms of overdose may vary based on the components:

Paracetamol Component: Early signs can include nausea, vomiting, pallor, and abdominal pain. A crucial feature is that the patient may initially be asymptomatic while serious damage develops.
Chlorphenamine & Caffeine Components: Signs may include convulsions, agitation, restlessness, confusion, tachycardia, or cardiac arrhythmias.

Severe Outcomes and Required Actions

Overdose poses a major risk of delayed, severe Liver Damage or Liver Failure due to the Paracetamol component. This can progress to encephalopathy and death. Other serious outcomes include Acute Renal Failure and severe neurological effects.

Mandatory Emergency Action:

Immediate medical attention or advice must be sought in the event of a suspected overdose, even if the person feels well.
Urgent hospitalisation is required for assessment and monitoring.
A blood test for the Paracetamol plasma concentration is mandatory to guide treatment, typically taken at four hours or later post-ingestion.

Official Management and Special Considerations

The required treatment involves the urgent administration of the specific antidote, N-acetylcysteine (NAC). Patients with underlying liver disease or who are glutathione depleted (e.g., due to starvation) are at a greater risk of severe hepatic toxicity. Children and the elderly are more susceptible to neurological effects, such as paradoxical excitation, from the Chlorphenamine component.

Therapeutic Uses of Intergrip

What Intergrip Treats: Main Uses and Benefits

This type of combination product is applied across domains where additional symptomatic support is needed in situations where patients experience acute upper respiratory infections. Intergrip is commonly used across conditions presenting with acute episodes, such as the common cold and flu-like syndromes.

The medication is relevant for easing symptoms related to inflammatory or irritative states, including excessive sneezing, runny nose, watery eyes, and helps with the concurrent discomfort of headache, generalized body aches, and febrile states. This combination is helpful in situations where multiple symptoms occur together, and supports patients during episodes of heightened discomfort.

“It is used when groups of symptoms appear suddenly or fluctuate by targeting multiple manifestations concurrently, helping to ease the overall burden of distress.”

The medication is used for managing mild to moderate pain. It also contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Relevant for Multi-Symptom Discomfort

Eligibility and Restrictions for Use

Eligibility Scope

Category	Population/Condition	Regulatory Status
Allowed	Adults and Adolescents	Use is approved for individuals 12 years of age and over.
Not Recommended	Children under 12	Not recommended for use.
Not Recommended	Pregnancy/Lactation	Not recommended for use; official documents advise avoidance.

Absolute Contraindications (Must Not Use)

Use of Intergrip is contraindicated and must be avoided in patients with the following conditions or circumstances:

Known hypersensitivity to any of the active ingredients (Paracetamol, Chlorphenamine, Caffeine).
Presence of Severe Hepatic Impairment or Severe Renal Impairment.
Closed-angle Glaucoma or Phaeochromocytoma.
Concurrent use of other Paracetamol-containing products.
Current treatment with or use of a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.
Uncontrolled Hypertension or serious Cardiovascular Disease.

Conditional Use and Restrictions

Regulatory documentation advises caution or restricted use for certain populations, including:

Patients with non-severe hepatic or renal dysfunction.
Elderly patients, particularly those with confusion.
Individuals with Prostatic Hypertrophy or certain other Cardiovascular diseases.

Connection to the overall eligibility profile: Official regulatory documents define eligibility through mandatory contraindications that strictly prohibit use in high-risk populations, coupled with "not recommended" classifications for children, pregnant, and breastfeeding groups. This structure establishes clear exclusionary criteria for the combination medicine.

What should I know about interactions with other medicines?

Intergrip's official interaction profile is defined by restrictions on specific combinations and documented changes in drug exposure or effect, as stated in regulatory documents.

Contraindicated and Restricted Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a formal contraindication, extending to a 14-day prohibition after MAOI use. The combination is also restricted with other Paracetamol-containing products to avoid overdose hazard, and with other Antihistamine-containing products due to the risk of additive central nervous system (CNS) depression.

Pharmacokinetic and Pharmacodynamic Interactions

The Chlorphenamine component is documented to inhibit the metabolism of Phenytoin, leading to an increased risk of toxicity. The anticoagulant effect of Warfarin is enhanced by the prolonged regular daily use of the Paracetamol component, which carries an increased risk of bleeding. The Caffeine component is documented to increase the elimination of Lithium from the body.

Timing, Substance, and Population Constraints

Alcohol (Ethanol) and CNS Depressants cause additive CNS depression and are restricted. In addition, intake of excessive dietary caffeine should be avoided. Regulatory documents note that elderly patients are more likely to experience the neurological anticholinergic effects of Chlorphenamine, and the overdose hazard of Paracetamol is formally noted as greater in those with underlying liver disease.

Mechanism of Action

Inhibition of Viral Integrase

Intergrip exerts its primary action by targeting and physically blocking a vital viral enzyme called integrase. This enzyme is crucial for the virus to permanently insert its genetic material into the DNA of the host cell. The binding of the drug prevents this integration, which interrupts the progression of the viral replication cycle.

Interruption of the Viral Replication Cycle

By preventing the integration of viral DNA, the drug effectively halts the entire downstream process of viral manufacturing within the affected cells. This disruption of the replication pathway leads to a reduction in the concentration of circulating viral particles in the body.

Influence on Immune Cell Dynamics

The mechanistic consequence of lowering the viral burden is the removal of a factor that typically mediates the destruction and suppression of key immune cells (such as T-cells). The resulting decrease in viral-mediated damage allows for altered immune cell concentration and activity, which is a physiological change resulting from the drug's mechanism.

Dosage and Administration Information

How Intergrip is Used: Official Administration Guidelines

Intergrip, a fixed-dose combination (FDC) tablet containing Paracetamol, Chlorphenamine, and Caffeine, is administered according to a specific, high-level protocol. This protocol focuses on short-term, symptomatic use.

Administration Scope

Feature	Guideline
Route of Administration	The approved route is oral administration. Tablets are to be swallowed whole with water and should not be crushed.
Standard Dosing	The typical single dose for adults is 1 to 2 tablets, taken only as needed for symptoms.
Frequency & Limits	Doses must be separated by a minimum interval of 4 to 6 hours and must not exceed the maximum daily dose of 8 tablets in 24 hours.
Duration Constraint	The medicine is intended for short-term use only, typically not exceeding 3 to 7 consecutive days for acute symptomatic relief.
Timing & Meals	The official label generally does not require specific timing in relation to meals.

Population-Specific Rules

Intergrip's standard adult regimen is not authorized for use in the pediatric population under 12 years. This restriction is a key component of the usage protocol, ensuring that the appropriate combination and strength are only administered to approved age groups. For individuals taking the medicine on a regular basis, a forgotten dose should not be compensated for by doubling the subsequent dose.

These instructions establish the procedural structure for administering the medicine, defining its use as a temporary, as-needed agent under strict frequency and duration limits.

Recent Clinical Evidence

Intergrip: Recent Clinical Evidence

Evidence for Symptomatic Relief of Common Cold and Flu-Like Syndromes

Research for this class of medicine research examined symptoms over time in individuals with the common cold and flu-like syndromes—conditions involving periods of heightened symptoms where discomfort can fluctuate. The evidence base primarily consists of short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies research examined outcomes related to systemic or functional imbalance by tracking how a wide range of symptoms changed over the study period, including Total Symptom Scores (TSS) and patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies regarding the composite change in multiple acute cold and flu symptoms over very short follow-up periods. Evidence for this combination is derived from the broader context on combination therapies applied in studies examining patient-reported experiences. The specific evidence for Intergrip is sometimes extrapolated from broader data due to variations in ingredient ratios across the studies reviewed.

Evidence for Acute Mild to Moderate Pain Relief

Research for the product’s pain-relief component was studied for conditions associated with acute or disruptive episodes, such as headache and general body aches. The focus here was in studies exploring the Paracetamol and Caffeine components. These trials research examined outcomes related to physical discomfort by measuring specific endpoints, including pain intensity and time to pain reduction. The evidence level for this component is classified as High. The studies monitored changes in pain scores associated with the Paracetamol-Caffeine combination, and data show patterns related to the measured time to achieve pain reduction when compared to Paracetamol alone. Evidence describes group patterns, not personal outcomes, in the acute pain setting.

Study Focus on Specific Populations

Clinical research studies explored which specific groups were included in the primary trials, mainly healthy adults and some data that was observed in older children. Data for certain groups remain insufficient, with limited information for long-term outcomes or dedicated research on special populations, such as pregnant individuals or those with various underlying health statuses.

Long-Term Research and Duration of Follow-Up

The majority of the foundational clinical research studies monitored outcomes over defined, short-term time intervals (48 to 72 hours up to 5 days). Because the follow-up durations were short, long-term effects are not fully established, and there is limited information for long-term outcomes. The research provides context about short-term changes measured during the study period, but study results reflect the specific conditions under which they were conducted.

Key Limitations and Areas of Scientific Uncertainty

Evidence quality varies across studies due to heterogeneity (variability) in the precise combination studied. Comparative evidence is lacking for this specific three-drug combination against every other multi-symptom cold product available. Research on the Chlorphenamine component specifically for pain relief evidence is limited, and follow-up durations were limited, meaning sustained use may have outcomes that are not fully captured by the current clinical trials.

Frequently Asked Questions (FAQ)

Common questions about Intergrip (FAQ)

Q: What is the main reason doctors prescribe Intergrip?

Official product information states that Intergrip is authorized for the symptomatic relief of discomfort associated with colds and flu. The authorized use includes addressing issues such as fever, headache, minor aches, and general pain.

Q: How long does it usually take for Intergrip to start working?

Studies and official information indicate that the medicine’s components start acting relatively quickly. For the pain-relief component, research suggests it typically reaches its maximum concentration in the blood within 30 to 60 minutes after taking a dose.

Q: Is it okay to drive after taking Intergrip?

The official product label includes an explicit warning regarding effects on the ability to drive or use machinery. Because the medicine can cause common side effects like drowsiness, dizziness, or blurred vision, caution is advised. Patients are advised to wait until they know how the medicine affects their level of alertness before driving or operating machinery.

Q: What is the difference between Intergrip and placebo in clinical trials?

Clinical research studies for Intergrip, particularly those examining its pain-relief components, compared the effects of the medicine to a placebo (an inactive substance). The evidence suggests that the drug has a statistically significant effect in providing symptom relief compared to those who took the placebo.

Q: What happens if I take Intergrip for longer than recommended?

According to regulatory documents, Intergrip is strictly intended for short-term use only, typically defined as 3 to 7 consecutive days. Taking the medicine for prolonged periods or in excess of the recommended dose is associated with a risk of serious organ damage, such as to the kidneys or liver.

Q: Are people with [Specific chronic condition, e.g., diabetes] allowed to use Intergrip?

Official regulatory documents advise caution when the medicine is used in people with certain existing chronic health conditions. This advisory is specifically mentioned for patients with conditions such as diabetes mellitus, liver disease, chronic bronchitis, or glaucoma.

Q: Does Intergrip have an immediate effect or does it build up over time?

Intergrip is intended to provide acute symptomatic relief, suggesting its effects are generally noticed soon after it is taken. It does not require a sustained "build-up" of concentration over several days to begin working effectively for short-term symptoms.

Q: What are the main research findings that led to Intergrip's approval?

The studies reviewed by regulatory agencies demonstrated significant improvement in patient-reported outcomes for both pain and general cold/flu symptoms. These findings, which suggested symptomatic relief, were used to support the medicine's approval for its intended uses.

Q: How often do serious side effects happen with Intergrip?

Regulatory documents classify serious adverse reactions, such as blood disorders or severe allergic/skin reactions, by frequency. These types of serious effects are generally classified as rare or very rare events, based on clinical experience and reporting.

Q: Can Intergrip cause weight changes?

While the complete regulatory side effect profile lists disorders related to metabolism and nutrition, specific changes in body weight (either gain or loss) are not typically listed as a common or expected side effect of this medicine.

Q: What is the risk of dependence or addiction with Intergrip?

Official regulatory texts address concerns about dependence and state that Intergrip is not generally considered habit-forming. This assessment aligns with its regulatory classification as a short-term, symptomatic relief medicine.

Q: Does Intergrip affect birth control pills?

Regulatory documents indicate that the Paracetamol component can interact with hormonal contraceptives containing ethinylestradiol. This interaction may result in an increased concentration of the contraceptive component in the bloodstream by slowing down its breakdown (metabolism).

Q: Will Intergrip interact with herbal supplements like St. John's Wort?

Official information warns of potential interactions with certain enzyme-inducing agents, which may include some herbal supplements like St. John's Wort. Combining these is associated with a possible increased risk of liver damage from the Paracetamol component of Intergrip.

Q: What should I do if a side effect of Intergrip feels severe?

Regulatory guidance advises that immediate medical attention should be sought if severe symptoms or an overdose are suspected. This is a standard safety measure for medicines that treat acute symptoms.

Q: How is Intergrip removed from the body?

The components of the medicine are primarily removed from the body after being processed through a natural process called metabolism. This processing involves liver enzymes, and the components are then eliminated from the body.

Q: What happens when you stop taking Intergrip?

Because this product is classified for short-term, as-needed use for acute symptoms, regulatory documents advise that stopping the medicine does not typically result in withdrawal symptoms.

Q: Does Intergrip require any special monitoring or blood tests?

Routine monitoring is not typically required during the standard use of the medicine. Official guidance specifies the need for monitoring liver and kidney functions in specific situations, such as when pre-existing hepatic or renal conditions are present, or in cases of potential overdose.

Q: What does 'contraindication' mean regarding Intergrip?

In regulatory documents, a 'contraindication' is a circumstance or condition under which the medicine must absolutely not be used. This term is used to identify situations where the potential risks of taking the medicine are described as outweighing any possible benefit.

Q: How long does Intergrip stay in your system after the last dose?

The body naturally processes the medicine after the last dose, and the concentration decreases over time. For example, the Paracetamol component has a half-life of 1 to 3 hours, meaning its presence is significantly reduced within a few hours after administration.

Q: Can Intergrip cause light sensitivity or vision changes?

The official list of potential undesirable effects includes vision changes, such as blurred vision, which aligns with the known profile of the Chlorphenamine component. Disturbances in attention are also noted in the safety information.

How should Intergrip be stored and disposed of?

Storage and Protection Requirements

Intergrip tablets must be stored at a controlled room temperature, generally defined as not exceeding 30 C (86 F), to maintain product stability. Regulatory instructions mandate keeping the product protected from light and moisture, and it must be stored away from excessive heat or conditions that could cause freezing. The medicine should be kept in its original container with the lid securely closed.

Child Safety and Disposal

It is a mandatory requirement that Intergrip, like all medicines, must be kept out of the sight and reach of children to prevent accidental ingestion. For disposal, unused or expired product must be discarded in accordance with local regulations and pharmacy take-back schemes, when available. The product should not be disposed of via household wastewater.

Intergrip